Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels

The effect of recombinant human erythropoietin (rHuEpo) on blood cells of adult and immature rats

Human recombinant erythropoietin is a synthetic hormone for treatment of some kinds of anemia. In this study, the effect of this hormone was investigated on blood cell changes in adult and immature rats. For this purpose, the hormone was administered at doses of 50, 100, and 200 IU/Kg (s.c.) twice a week for a period of 6 weeks. Then, the number of red blood cells (RBC), subtypes of white blood...

ameliorative effect of recombinant human erythropoietin and ischemic preconditioning on renal ischemia reperfusion injury in rats

conclusions pretreatment with epo and application of ipc significantly ameliorated the renal injury induced by bilateral renal ir. however, both treatments attenuated renal dysfunction and oxidative stress in kidney tissues. there were no significant differences between pretreatment with epo or application of ipc. materials and methods twenty four male wistar rats were allocated into four exper...

Ameliorative Effect of Recombinant Human Erythropoietin and Ischemic Preconditioning on Renal Ischemia Reperfusion Injury in Rats.

BACKGROUND Ischemia-reperfusion (IR) injury is one of the most common causes of renal dysfunction. There is increasing evidence about the role of the reactive oxygen species (ROS) in these injuries and endogenous antioxidants seem to have an important role in decreasing the renal tissue injury. OBJECTIVES The aim of this study was to compare the effect of recombinant human erythropoietin (EPO...

Treatment of renal anemia with recombinant human erythropoietin.

The physical performance of 12 anemic patients on renal dialysis was investigated following treatment of renal anemia with recombinant human erythropoietin (rhEPO; 40-120 U/kg, 3 times a week). Exercise intensity at a heart rate of 130 beats/min (PWC130) on a bicycle ergometer was assessed before rhEPO treatment, after reaching the target hematocrit (73 +/- 18 days), and in the maintenance phas...

the impact of human recombinant erythropoietin on renal function in patients with chronic kidney disease